AU2021218578A1 - Methods of treating Fabry disease - Google Patents

Methods of treating Fabry disease Download PDF

Info

Publication number
AU2021218578A1
AU2021218578A1 AU2021218578A AU2021218578A AU2021218578A1 AU 2021218578 A1 AU2021218578 A1 AU 2021218578A1 AU 2021218578 A AU2021218578 A AU 2021218578A AU 2021218578 A AU2021218578 A AU 2021218578A AU 2021218578 A1 AU2021218578 A1 AU 2021218578A1
Authority
AU
Australia
Prior art keywords
patient
migalastat
assessing
therapy
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021218578A
Other languages
English (en)
Inventor
Nina SKUBAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicus Therapeutics Inc
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of AU2021218578A1 publication Critical patent/AU2021218578A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2021218578A 2020-02-10 2021-02-10 Methods of treating Fabry disease Pending AU2021218578A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062972392P 2020-02-10 2020-02-10
US62/972,392 2020-02-10
PCT/US2021/017446 WO2021163183A1 (en) 2020-02-10 2021-02-10 Methods of treating fabry disease

Publications (1)

Publication Number Publication Date
AU2021218578A1 true AU2021218578A1 (en) 2022-08-25

Family

ID=77272302

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021218578A Pending AU2021218578A1 (en) 2020-02-10 2021-02-10 Methods of treating Fabry disease

Country Status (11)

Country Link
US (1) US20210251972A1 (https=)
EP (2) EP4732901A2 (https=)
JP (1) JP2023513700A (https=)
KR (1) KR20220150902A (https=)
AU (1) AU2021218578A1 (https=)
CA (1) CA3167476A1 (https=)
DK (1) DK4103178T3 (https=)
FI (1) FI4103178T3 (https=)
LT (1) LT4103178T (https=)
PT (1) PT4103178T (https=)
WO (1) WO2021163183A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3224546C (en) 2017-05-30 2026-02-24 Amicus Therapeutics, Inc. Use of migalastat in the treatment of fabry patients
KR20200128676A (ko) 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
US12594268B2 (en) * 2018-08-20 2026-04-07 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
TW202408513A (zh) * 2016-07-19 2024-03-01 美商阿米庫斯醫療股份有限公司 治療ert初治的和已經歷ert的患者中之法布瑞氏症

Also Published As

Publication number Publication date
CA3167476A1 (en) 2021-08-19
LT4103178T (lt) 2026-04-10
EP4732901A2 (en) 2026-04-29
FI4103178T3 (fi) 2026-03-23
EP4103178A1 (en) 2022-12-21
DK4103178T3 (da) 2026-03-30
EP4103178B1 (en) 2025-12-24
PT4103178T (pt) 2026-03-30
US20210251972A1 (en) 2021-08-19
EP4103178A4 (en) 2024-03-20
KR20220150902A (ko) 2022-11-11
WO2021163183A1 (en) 2021-08-19
JP2023513700A (ja) 2023-04-03

Similar Documents

Publication Publication Date Title
AU2023206175B2 (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
US12280042B2 (en) Methods of treating fabry patients having renal impairment
US20240277687A1 (en) Methods of treating fabry disease in patients having a mutation in the gla gene
EP4103178A1 (en) Methods of treating fabry disease
WO2019046244A1 (en) METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE
EP3982962A1 (en) Methods of treating fabry disease in patients having renal impairment
EP4114390B1 (en) Methods of treating fabry disease in patients having a mutation in the gla gene
EP3914247A1 (en) Use of migalostat in reducing the risk of cerebrovascular event in patients with fabry disease
EP4370120A1 (en) Methods of treating fabry disease in pediatric patients
AU2018220047A1 (en) A method for treatment of fabry disease
HK40104071A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40122460A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40128496A (en) Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
HK40105450A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104441A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
EA045263B1 (ru) Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри